SCIENTIFIC POSTER

Real World Evidence by Gina Tsanaktsidis, Veena Valan Arasu, Australia


ABSTRACT

Aim:

To analyse one-year outcomes of a treat and extend {T & E} treatment regimen using intravitreal aflibercept in patients with either neovascular age related macular degeneration (nAMD) or diabetic macular oedema (DMO) in routine clinical practice.

Design:

Database retrospective study utilising medical records from two private clinical practices managed by the same surgeon.

Participants:

The population included both treatment naive and switch patients with nAMD or DMO treated with aflibercept monotherapy.

Primary Outcome Measures:

Mean number of intravitreal injections during the study period; mean gain in visual acuity from baseline to 12 months; and mean change in central retinal thickness from baseline to 12 months.

Results:

The study population comprised 34 eyes of 27 nAMD patients and 20 eyes of 16 DMO patients completing 12 months of follow up. In the nAMD group, mean age was 83.93 (8.01), of which 47.06% were females. Mean gain in visual acuity from baseline to 12 months was 3.24 letters (10.33). Mean change in central retinal thickness was 31.00 micrometers (87.33). Mean number of injections was 7.44 (1.80). In the DMO group, mean age was 74.94 (11.81), of which 43.75% were females. Mean gain in visual acuity from baseline to 12 months was 3.79 letters (11.78). Mean change in central retinal thickness was 60.25 micrometers (132.64). Mean number of injections was 3.15 (1.79).

Conclusions:

Our results demonstrate that aflibercept monotherapy in nAMD and DMO patients using a treat and extend regimen in a real-world setting can achieve good visual outcomes comparable to large randomized controlled trials.


CONTACT DETAILS

Gina Tsanaktsidis, Veena Valan Arasu
Burwood Eye Clinic
Sydney
Australia
Email : superstrings8@bigpond.com
Cell Phone: +61431856818
Work Phone: +6197473065